Recent advances in antigen-targeted therapy in non-Hodgkin's lymphoma.
Substantial advances in antigen-targeted lymphoma therapy have been achieved in recent years that make the use of monoclonal antibodies a highly attractive concept and promise further improvements in the clinical management of malignant lymphoma. The development of the chimeric anti-CD20 antibody IDEC-C2B8 (Rituximab) proved the concept of an effective therapy with a single unconjugated monoclonal antibody in lymphoma patients. Radioimmunoconjugates with myeloablative activity induced response rates of 80-100% in heavily pretreated patients. Progress in the genetic engineering of immunotoxins has improved the efficacy of these constructs. Ongoing prospective clinical trials will define the optimal use of these innovative therapeutic agents in patients with malignant lymphoma, and may establish therapeutic strategies with a high anti-lymphoma specificity and a low unspecific toxicity.
Feuring-Buske
M
M
Medizinische Klinik III, Klinikum Grosshadern, Ludwig-Maximilians Universität, Munich, Germany. michaela@terryfox.ubc.ca
Buske
C
C
Unterhalt
M
M
Hiddemann
W
W
D018033:Antibodies, Bispecific; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D000941:Antigens / Q000276:immunology*; D002986:Clinical Trials as Topic; D006801:Humans; D018796:Immunoconjugates / Q000627:therapeutic use; D007167:Immunotherapy / Q000639:trends; D000922:Immunotoxins / Q000627:therapeutic use; D007457:Iodine Radioisotopes; D016393:Lymphoma, B-Cell / Q000188:drug therapy; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy*; D011993:Recombinant Fusion Proteins / Q000276:immunology
D018033:Antibodies, Bispecific; D000911:Antibodies, Monoclonal; D000941:Antigens; D018796:Immunoconjugates; D000922:Immunotoxins; D007457:Iodine Radioisotopes; D011993:Recombinant Fusion Proteins